Platelet Factor 4 Antibody Persistence and Long-term Pathogenicity in Vaccine-induced Immune Thrombotic Thrombocytopenia.

ABSTRACT: Rarely, recipients of adenoviral vector-based vaccines experience a severe thrombotic thrombocytopenic condition referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT). VITT is a transient prothrombotic process, although recent data suggests that VITT anti-platelet factor 4 (PF4) antibodies are more persistent than antibodies seen in heparin-induced thrombocytopenia. Whether anti-PF4 antibody persistence in VITT is related to the continued persistence of antibody clones from the acute phase or the development of novel antibodies is unclear. To study this, acute and follow-up samples were obtained from six Ad26.COV2.S-associated VITT patients, with a median time to follow-up of 244 days from acute presentation (Range, 114-664 days). Upon affinity-enrichment of antibodies,

SUBMITTER: Kanack A 

PROVIDER: S-EPMC12676393 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature